Hippocampal ProNGF signaling pathways and β-amyloid levels in mild cognitive impairment and alzheimer disease

Elliott J. Mufson, Bin He, Muhammad Nadeem, Sylvia E. Perez, Scott E. Counts, Sue Leurgans, Jason Fritz, James Lah, Stephen D. Ginsberg, Joanne Wuu, Stephen W. Scheff

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Hippocampal precursor of nerve growth factor (proNGF)/NGF signaling occurs in conjunction with A-amyloid (Aβ) accumulations in Alzheimer disease (AD). To assess the involvement of this pathway in AD progression, we quantified these proteins and their downstream pathway activators in postmortem tissues from the brains of subjects with no cognitive impairment (NCI), mild cognitive impairment (MCI), and AD using immunoblotting and ELISA. Hippocampal proNGF was significantly greater in AD cases compared with those in NCI and MCI cases. TrkA was significantly reduced in MCI compared with those in NCI and AD, whereas p75 neurotrophin receptor, sortilin, and neurotrophin receptor homolog 2 remained stable. Akt decreased from NCI to MCI to AD, whereas phospho- Akt and phospho-AktYtoYAkt ratio were elevated in AD compared with those in MCI and NCI. No differences were found in phospho- Erk, Erk, or their ratio across groups. Although c-jun kinase (JNK) remained stable across groups, phospho-JNK and the phospho- JNKYtoYJNK ratio increased significantly in AD compared with those in NCI and MCI. Expression levels of Aβ1-40, Aβ 1-42, and Aβ40/42 ratio were stable. Statistical analysis revealed a strong positive correlation between proNGF and phospho-JNK, although only proNGF was negatively correlated with cognitive function and only TrkA was negatively associated with pathologic criteria. These findings suggest that alterations in the hippocampal NGF signaling pathway in MCI and AD favor proNGF-mediated proapoptotic pathways, and that this is independent of Aβ accumulation during AD progression.

Original languageEnglish
Pages (from-to)1018-1029
Number of pages12
JournalJournal of Neuropathology and Experimental Neurology
Volume71
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Amyloid
Alzheimer Disease
Nerve Growth Factor
Phosphotransferases
Cognitive Dysfunction
Disease Progression
Nerve Growth Factor Receptors
Nerve Growth Factor Receptor
Immunoblotting
Cognition
Enzyme-Linked Immunosorbent Assay

Keywords

  • Alzheimer disease
  • Amyloid
  • Mild cognitive impairment
  • Nerve growth factor
  • ProNGF
  • Protein kinases
  • TrkA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Hippocampal ProNGF signaling pathways and β-amyloid levels in mild cognitive impairment and alzheimer disease. / Mufson, Elliott J.; He, Bin; Nadeem, Muhammad; Perez, Sylvia E.; Counts, Scott E.; Leurgans, Sue; Fritz, Jason; Lah, James; Ginsberg, Stephen D.; Wuu, Joanne; Scheff, Stephen W.

In: Journal of Neuropathology and Experimental Neurology, Vol. 71, No. 11, 01.11.2012, p. 1018-1029.

Research output: Contribution to journalArticle

Mufson, EJ, He, B, Nadeem, M, Perez, SE, Counts, SE, Leurgans, S, Fritz, J, Lah, J, Ginsberg, SD, Wuu, J & Scheff, SW 2012, 'Hippocampal ProNGF signaling pathways and β-amyloid levels in mild cognitive impairment and alzheimer disease', Journal of Neuropathology and Experimental Neurology, vol. 71, no. 11, pp. 1018-1029. https://doi.org/10.1097/NEN.0b013e318272caab
Mufson, Elliott J. ; He, Bin ; Nadeem, Muhammad ; Perez, Sylvia E. ; Counts, Scott E. ; Leurgans, Sue ; Fritz, Jason ; Lah, James ; Ginsberg, Stephen D. ; Wuu, Joanne ; Scheff, Stephen W. / Hippocampal ProNGF signaling pathways and β-amyloid levels in mild cognitive impairment and alzheimer disease. In: Journal of Neuropathology and Experimental Neurology. 2012 ; Vol. 71, No. 11. pp. 1018-1029.
@article{8ae5deb1cd6a49ee80d7ab9a66fb2d2e,
title = "Hippocampal ProNGF signaling pathways and β-amyloid levels in mild cognitive impairment and alzheimer disease",
abstract = "Hippocampal precursor of nerve growth factor (proNGF)/NGF signaling occurs in conjunction with A-amyloid (Aβ) accumulations in Alzheimer disease (AD). To assess the involvement of this pathway in AD progression, we quantified these proteins and their downstream pathway activators in postmortem tissues from the brains of subjects with no cognitive impairment (NCI), mild cognitive impairment (MCI), and AD using immunoblotting and ELISA. Hippocampal proNGF was significantly greater in AD cases compared with those in NCI and MCI cases. TrkA was significantly reduced in MCI compared with those in NCI and AD, whereas p75 neurotrophin receptor, sortilin, and neurotrophin receptor homolog 2 remained stable. Akt decreased from NCI to MCI to AD, whereas phospho- Akt and phospho-AktYtoYAkt ratio were elevated in AD compared with those in MCI and NCI. No differences were found in phospho- Erk, Erk, or their ratio across groups. Although c-jun kinase (JNK) remained stable across groups, phospho-JNK and the phospho- JNKYtoYJNK ratio increased significantly in AD compared with those in NCI and MCI. Expression levels of Aβ1-40, Aβ 1-42, and Aβ40/42 ratio were stable. Statistical analysis revealed a strong positive correlation between proNGF and phospho-JNK, although only proNGF was negatively correlated with cognitive function and only TrkA was negatively associated with pathologic criteria. These findings suggest that alterations in the hippocampal NGF signaling pathway in MCI and AD favor proNGF-mediated proapoptotic pathways, and that this is independent of Aβ accumulation during AD progression.",
keywords = "Alzheimer disease, Amyloid, Mild cognitive impairment, Nerve growth factor, ProNGF, Protein kinases, TrkA",
author = "Mufson, {Elliott J.} and Bin He and Muhammad Nadeem and Perez, {Sylvia E.} and Counts, {Scott E.} and Sue Leurgans and Jason Fritz and James Lah and Ginsberg, {Stephen D.} and Joanne Wuu and Scheff, {Stephen W.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1097/NEN.0b013e318272caab",
language = "English",
volume = "71",
pages = "1018--1029",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Hippocampal ProNGF signaling pathways and β-amyloid levels in mild cognitive impairment and alzheimer disease

AU - Mufson, Elliott J.

AU - He, Bin

AU - Nadeem, Muhammad

AU - Perez, Sylvia E.

AU - Counts, Scott E.

AU - Leurgans, Sue

AU - Fritz, Jason

AU - Lah, James

AU - Ginsberg, Stephen D.

AU - Wuu, Joanne

AU - Scheff, Stephen W.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Hippocampal precursor of nerve growth factor (proNGF)/NGF signaling occurs in conjunction with A-amyloid (Aβ) accumulations in Alzheimer disease (AD). To assess the involvement of this pathway in AD progression, we quantified these proteins and their downstream pathway activators in postmortem tissues from the brains of subjects with no cognitive impairment (NCI), mild cognitive impairment (MCI), and AD using immunoblotting and ELISA. Hippocampal proNGF was significantly greater in AD cases compared with those in NCI and MCI cases. TrkA was significantly reduced in MCI compared with those in NCI and AD, whereas p75 neurotrophin receptor, sortilin, and neurotrophin receptor homolog 2 remained stable. Akt decreased from NCI to MCI to AD, whereas phospho- Akt and phospho-AktYtoYAkt ratio were elevated in AD compared with those in MCI and NCI. No differences were found in phospho- Erk, Erk, or their ratio across groups. Although c-jun kinase (JNK) remained stable across groups, phospho-JNK and the phospho- JNKYtoYJNK ratio increased significantly in AD compared with those in NCI and MCI. Expression levels of Aβ1-40, Aβ 1-42, and Aβ40/42 ratio were stable. Statistical analysis revealed a strong positive correlation between proNGF and phospho-JNK, although only proNGF was negatively correlated with cognitive function and only TrkA was negatively associated with pathologic criteria. These findings suggest that alterations in the hippocampal NGF signaling pathway in MCI and AD favor proNGF-mediated proapoptotic pathways, and that this is independent of Aβ accumulation during AD progression.

AB - Hippocampal precursor of nerve growth factor (proNGF)/NGF signaling occurs in conjunction with A-amyloid (Aβ) accumulations in Alzheimer disease (AD). To assess the involvement of this pathway in AD progression, we quantified these proteins and their downstream pathway activators in postmortem tissues from the brains of subjects with no cognitive impairment (NCI), mild cognitive impairment (MCI), and AD using immunoblotting and ELISA. Hippocampal proNGF was significantly greater in AD cases compared with those in NCI and MCI cases. TrkA was significantly reduced in MCI compared with those in NCI and AD, whereas p75 neurotrophin receptor, sortilin, and neurotrophin receptor homolog 2 remained stable. Akt decreased from NCI to MCI to AD, whereas phospho- Akt and phospho-AktYtoYAkt ratio were elevated in AD compared with those in MCI and NCI. No differences were found in phospho- Erk, Erk, or their ratio across groups. Although c-jun kinase (JNK) remained stable across groups, phospho-JNK and the phospho- JNKYtoYJNK ratio increased significantly in AD compared with those in NCI and MCI. Expression levels of Aβ1-40, Aβ 1-42, and Aβ40/42 ratio were stable. Statistical analysis revealed a strong positive correlation between proNGF and phospho-JNK, although only proNGF was negatively correlated with cognitive function and only TrkA was negatively associated with pathologic criteria. These findings suggest that alterations in the hippocampal NGF signaling pathway in MCI and AD favor proNGF-mediated proapoptotic pathways, and that this is independent of Aβ accumulation during AD progression.

KW - Alzheimer disease

KW - Amyloid

KW - Mild cognitive impairment

KW - Nerve growth factor

KW - ProNGF

KW - Protein kinases

KW - TrkA

UR - http://www.scopus.com/inward/record.url?scp=84871204757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871204757&partnerID=8YFLogxK

U2 - 10.1097/NEN.0b013e318272caab

DO - 10.1097/NEN.0b013e318272caab

M3 - Article

VL - 71

SP - 1018

EP - 1029

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 11

ER -